Jazz Pharmaceuticals' Ziihera plus chemotherapy cuts death risk 24% in Phase 3 gastroesophageal cancer trial

By Public Technologies
  • Jazz Pharmaceuticals presented updated Phase 3 Ziihera survival results in first-line HER2-positive advanced gastroesophageal adenocarcinoma at ESMO 2026.
  • Ziihera with chemotherapy significantly improved overall survival versus trastuzumab with chemotherapy.
  • Adding tislelizumab sustained survival benefits versus trastuzumab with chemotherapy, but did not significantly improve survival over Ziihera with chemotherapy.
  • Safety profiles remained unchanged with longer follow-up.
  • The FDA cleared both Ziihera regimens on August 25, 2026, for first-line treatment in specified HER2-positive patient groups.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610231015PR_NEWS_USPR_____SF78826) on October 23, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk